Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir in CIN 2/3
NCT01925378Phase 2Withdrawn
- Sponsor
- UTHealth Houston
- Start
- Nov 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelfinavir in cervical intraepithelial neoplasia (CIN), sponsored by UTHealth Houston. Primary endpoint: Efficacy of Nelfinavir to induce complete remission or partial regression at 24 weeks. Planned start Nov 2018; status: withdrawn.
02
Drugs
nelfinavir
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT01925378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01925378.